04.27.2026
Glaukos’ CXL Therapy, Epioxa, Meets Primary Endpoint in Phase 3 Clinical Trial
Key Takeaways Results of a phase 3 confirmatory pivotal trial for Epioxa (Glaukos), an FDA-approved therapy for keratoconus, were published in Ophthalmology and Therapy. Treatment with Epioxa led to a statistically significant improvement in Kmax at month 12 (-0.5 D improvement in Epioxa-treated eyes versus +0.4 D worsening in the sham group).